Disclosure of the exercise status of stock acquisition rights on a monthly basis. The target month is July 2026, with 2,209,800 shares issued, an exercise rate of 16.24%, and total unexercised remaining shares reduced to 7,137. Exercise dates span multiple days from July 1 to July 31.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4583","jir_company_name":"Kaio Medical Science Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4583-20260803-01.pdf","jir_short_summary":"Disclosure of the exercise status of stock acquisition rights on a monthly basis. The target month is July 2026, with 2,209,800 shares issued, an exercise rate of 16.24%, and total unexercised remaining shares reduced to 7,137. Exercise dates span multiple days from July 1 to July 31.","jir_summary":"### Overview of Results\nThis disclosure is an update on the monthly exercise status of the 23rd stock acquisition rights (with exercise price adjustment provisions). The number of issued shares is 2,209,800, the total number exercised this month is not disclosed, but the exercise rate is 16.24%. Unexercised remaining shares have decreased significantly from the previous month, indicating impacts on liquidity and potential dilution.\n\n### Impact on Shareholders \/ Outlook\nThe decline in unexercised remaining shares may help curb potential future dilution. However, since exercise dates involve monthly dispersion of share issuances, future exercise trends could cause changes in the number of shares and the dilution rate.","jir_financial_highlights":"Number of Shares Issued During the Target Month: 2,209,800 shares (Unknown)\nExercise Count and Exercise Ratio Against Total Issued: 22,098 (16.24% of issued total) (Unknown)\nTotal Unexercised Remaining: From 29,235 shares in the previous month to 7,137 shares this month (Significant decrease)","jir_category":"","jir_hashtags":"#KaioBiotechnology, #IR, #JapanStocks","jir_key_figures":"Target Month Issued Shares: 2,209,800 shares\nTarget Month Exercise Rate: 16.24%\nUnexercised Remaining Shares: 7,137 shares","jir_meta_title":"[Kaio Biotech Co., Ltd.] Monthly Exercise Status of Stock Acquisition Rights Published | July 2026","jir_meta_description":"Kaio Biotech Co., Ltd. publishes the monthly exercise status of stock acquisition rights. Issued shares 2,209,800; exercise rate 16.24%; unexercised remaining 7,137 shares; attention to future dilution trends.","jir_og_title":"[Kaio Biotech] Monthly Exercise Status of Stock Acquisition Rights Published | July 2026","jir_og_description":"Monthly exercise status for stock acquisition rights in July. Issued shares 2,209,800; exercise rate 16.24%; unexercised remaining 7,137 shares.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59315,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-92717","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n